In this study, we used a panel of authenticated thyroid cancer cell lines carrying wild-type TP53 or mutant-type TP53 to test the therapeutic potential of NVP-BEZ235 and attempted to understand its anticarcinogenic mechanisms in thyroid cancer. Here, TP53 is linked to thyroid gland carcinoma.